Stem Cell Therapeutics Corp. Granted Patent Portfolio and Expand Geographic Coverage of Key Stem Cell Technologies
August 18 2011 - 6:00AM
Marketwired
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS) ("SCT" or the
"Company") announces that it has received notification of the
issuance of two new patents. The first entitled "Stimulation of
Proliferation of Pluripotent Stem Cells through Administration of
Pregnancy Associated Compounds" was granted by the United States
Patent office; Patent number: 7,994,131. The second is entitled
"Oligodendrocyte Production from Multipotent Neural Stem Cells" and
was issued by the Japan Patent Office; Patent number: 4783013.
The first patent relates to the use of the pregnancy hormone
human chorionic gonadotropin (hCG) to treat patients presenting
with damaged or diseased heart cells.
The second patent adds yet another important territory to SCT's'
family of patents relating to the use of granulocyte colony
stimulating factor (GM-CSF) to treat white matter disorders by
increasing the number of stem cells available to form CNS
oligodendrocytes. White matter disorders include demyelinating
diseases that include Multiple Sclerosis, Acute Disseminating
Encephalomyelitis, Diffuse Cerebral Sclerosis, and Spinal Cord
Injury.
Dr. Allen Davidoff, Chief Scientific Officer of Stem Cell
Therapeutics Corp. commented "The rapid succession of granted
patents in both neurology and now cardiology is a welcome
development for Stem Cell Therapeutics Corp. Years of steadfast
work by the Stem Cell Therapeutics scientists, staff and agents
continues to build a valuable, world class patent portfolio. We are
particularly excited by the first patent issued. This patent
protects the newly discovered potential use of hCG for post heart
attack recovery, and permits the development of new therapies in a
large therapeutic market."
About Stem Cell Therapeutics Corp.:
Stem Cell Therapeutics Corp. is a public biotechnology company
principally developing for commercialization drug-based therapies
to treat central nervous system diseases. SCT is a leader in the
development of therapies that utilize drugs to stimulate a
patient's own resident stem cells. The company's programs aim to
repair brain and nerve function lost due to disease or injury.
SCT's extensive patent portfolio of owned and licensed intellectual
property supports the potential expansion into future clinical
programs in numerous neurological diseases such as stroke,
traumatic brain injury, multiple sclerosis, Huntington's disease,
Alzheimer's disease, and ALS.
Caution Regarding Forward-Looking Information:
Certain statements contained in this press release constitute
forward-looking information within the meaning of applicable
Canadian provincial securities legislation (collectively, the
"forward-looking statements"). These forward-looking statements
relate to, among other things, SCT's objectives, goals, targets,
strategies, intentions, plans, beliefs, estimates and outlook, and
can, in some cases, be identified by the use of words such as
"believe," "anticipate," "expect," "intend," "plan," "will," "may"
and other similar expressions. In addition, any statements that
refer to expectations, projections or other characterizations of
future events or circumstances are forward-looking statements.
These statements reflect management's current beliefs and are based
on information currently available to management. Certain material
factors or assumptions are applied in making forward-looking
statements, and actual results may differ materially from those
expressed or implied in such statements. Important factors that
could cause actual results to differ materially from these
expectations include, among other things: uncertainties and risks
related to, the availability of capital, changes in capital
markets, uncertainties related to clinical trials and product
development, rapid technological change, uncertainties related to
forecasts, competition, potential product liability, unproven
markets for technologies in development, the cost and supply of raw
materials, management of growth, effects of payors' willingness to
pay for products, risks related to regulatory matters and risks
related to intellectual property matters. Additional information
about these factors and about the material factors or assumptions
underlying such forward-looking statements may be found in the body
of this news release, as well as under the heading "Risk Factors"
contained in SCT's 2010 annual information form. SCT cautions that
the foregoing list of important factors that may affect future
results is not exhaustive.
When relying on SCT's forward-looking statements to make
decisions with respect to SCT, investors and others should
carefully consider the foregoing factors and other uncertainties
and potential events. Such forward-looking statements are based on
a number of estimates and assumptions which may prove to be
incorrect, including, but not limited to, assumptions regarding the
availability of financing for research and development companies in
addition to general business and economic conditions. These risks
and uncertainties should be considered carefully and investors and
others should not place undue reliance on the forward-looking
statements. Although the forward-looking statements contained in
this press release are based upon what management believes to be
reasonable assumptions, SCT cannot provide assurance that actual
results will be consistent with these forward-looking statements.
SCT undertakes no obligation to update or revise any
forward-looking statement.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contacts: Stem Cell Therapeutics Corp. Dr. Allen Davidoff, PhD,
CSO 403-245-5495 ext.226 adavidoff@stemcellthera.com
www.stemcellthera.com
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024